The “Understanding Pyoderma Gangrenosum, Review and Assessment of Disease Effects (UPGRADE)” Project: a protocol for the development of the core outcome domain set for trials in pyoderma gangrenosum

[1]  S. Fei,et al.  Molecular and cellular characterization of pyoderma gangrenosum: Implications for the use of gene expression. , 2021, The Journal of investigative dermatology.

[2]  M. Mathur,et al.  Pyoderma gangrenosum , 2020, Nature Reviews Disease Primers.

[3]  Marlen Niederberger,et al.  Delphi Technique in Health Sciences: A Map , 2020, Frontiers in Public Health.

[4]  H. Williams,et al.  Outcome assessment in dermatology clinical trials and cochrane reviews: call for a dermatology‐specific outcome taxonomy , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

[5]  W. Huang,et al.  Identification and evaluation of outcome measurement instruments in pyoderma gangrenosum: a systematic review * , 2020, The British journal of dermatology.

[6]  H. Williams,et al.  Navigating the landscape of core outcome set development in dermatology. , 2019, Journal of the American Academy of Dermatology.

[7]  M. Rustin,et al.  Pyoderma gangrenosum - a guide to diagnosis and management . , 2019, Clinical medicine.

[8]  M. Suarez‐Almazor,et al.  Core Outcome Sets Specifically for Longterm Observational Studies: OMERACT Special Interest Group Update in Rheumatoid Arthritis , 2019, The Journal of Rheumatology.

[9]  H. Williams,et al.  Core outcome sets in dermatology: report from the second meeting of the International Cochrane Skin Group Core Outcome Set Initiative , 2018, The British journal of dermatology.

[10]  Rosie Qin,et al.  Diagnostic Criteria of Ulcerative Pyoderma Gangrenosum: A Delphi Consensus of International Experts , 2018, JAMA dermatology.

[11]  P. Williamson,et al.  A taxonomy has been developed for outcomes in medical research to help improve knowledge discovery , 2017, Journal of clinical epidemiology.

[12]  Jane M Blazeby,et al.  Core Outcome Set-STAndards for Development: The COS-STAD recommendations , 2017, PLoS medicine.

[13]  Angus G K McNair,et al.  The COMET Handbook: version 1.0 , 2017, Trials.

[14]  A. Gottlieb,et al.  Protocol for the development of a core domain set for hidradenitis suppurativa trial outcomes , 2017, BMJ Open.

[15]  P. Williamson,et al.  The use of qualitative methods to inform Delphi surveys in core outcome set development , 2016, Trials.

[16]  T. Marhadour,et al.  Anakinra Improves Pyoderma Gangrenosum in Psoriatic Arthritis: A Case Report. , 2015, Annals of internal medicine.

[17]  M. Picardo,et al.  Developing core outcome set for vitiligo clinical trials: international e‐Delphi consensus , 2015, Pigment cell & melanoma research.

[18]  R. Sivamani,et al.  Effective Strategies for the Management of Pyoderma Gangrenosum. , 2012, Advances in wound care.

[19]  L. Naldi,et al.  Challenges for Synthesising Data in a Network of Registries for Systemic Psoriasis Therapies , 2012, Dermatology.

[20]  P. Glasziou,et al.  Avoidable waste in the production and reporting of research evidence , 2009, The Lancet.

[21]  H. Williams,et al.  The Harmonizing Outcome Measures for Eczema (HOME) roadmap: a methodological framework to develop core sets of outcome measurements in dermatology. , 2015, The Journal of investigative dermatology.